TrialPloS one2020

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

John Devin Peipert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.